Clinical trials: Complement System
Acute Ischemic Stroke
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
Single-chain urokinase-type plasminogen activator (pro-urokinase) is a highly effective thrombolytic drug. At pharmacologic concentrations however, pro-urokinase is converted to urokinase - a non specific thrombolytic, limiting…
- Trial name
- NCT01694381
- Testing
- M5, C1-inhibitor
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- TSI, LLC
Platelet Storage
Effect of Platelet Storage on Complement Activation
Platelet units are stored and complement factors are evaluated
- Trial name
- NCT03280823
- Volunteers
- 10 people
- Sponsor
- Shimaa Abdeleem
C3 Glomerulopathy, IgA Nephropathy
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy [C3G]…
- Trial name
- NCT05083364
- Testing
- ARO-C3
- Where
- 16 sites in Australia, Georgia and 5 more
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Cardiopulmonary Bypass, Inflammatory Response
Platelets and Complement Activation in Coronary Artery Bypass Graft Surgery (CABG)
Patients undergoing coronary artery bypass graft surgery (CABG) frequently exhibit postoperative bleeding complications which are still a major cause for morbidity and mortality.
- Conditions
- Cardiopulmonary Bypass, Inflammatory Response, Platelet Dysfunction
- Trial name
- PAC (NCT05033236)
- Where
- Austria
- Volunteers
- 190 people
- Sponsor
- Medical University Innsbruck
Hereditary Angioedema, HAE
Oral Berotralstat Expanded Access Program
This expanded access program will provide access to berotralstat for eligible participants with hereditary angioedema in the U.S.
- Conditions
- Hereditary Angioedema, HAE, Prophylaxis
- Trial name
- NCT04428632
- Testing
- Berotralstat
- Sponsor
- BioCryst Pharmaceuticals
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT00963872
- Testing
- cyclophosphamide, fludarabine phosphate, Total body irradiation
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Angioedema
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be…
- Trial name
- NCT00125151
- Testing
- C1 inhibitor concentrate (C1-esteraseremmer-N)
- Where
- 3 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Prothya Biosolutions
Multiple Sclerosis
Impact of Virtual Reality Physiotherapy on Multiple Sclerosis Patients
The goal of this clinical trial is to learn if virtual reality combined with conventional physiotherapy intervention works to treat moderate to severe multiple sclerosis persons.
- Trial name
- NCT06735053
- Testing
- Virtual Reality group
- Where
- 2 sites in Spain
- Volunteers
- 26 people
- Sponsor
- European University of Madrid
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care.
- Trial name
- MOBILIZE (NCT06290128)
- Testing
- Riliprubart
- Where
- 132 sites in United States, Argentina and 22 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease
Amyotrophic Lateral Sclerosis and the Innate Immune System
Amyotrophic Lateral Sclerosis (ALS) is an aggressive, deadly disease. ALS leads to destruction of the neural pathways which control the conscious movements of the muscles.
- Conditions
- Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- NCT02869048
- Where
- 8 sites in Denmark
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hereditary Angioedema (HAE)
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
The purpose of this study is to evaluate the efficacy and safety of repeated doses of ecallantide in the treatment of acute attacks of hereditary angioedema and to allow HAE patients continued access to ecallantide.
- Trial name
- NCT00456508
- Testing
- ecallantide
- Where
- 41 sites in United States, Canada and 1 more
- Volunteers
- 147 people
- Sponsor
- Shire
Complement 3 Glomerulopathy
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain
This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
- Trial name
- ROUTE-C3G (NCT07598448)
- Where
- 2 sites in Spain
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Acute Appendicitis
Complement Diagnosis of Acute Appendicitis
Acute appendicitis is a common condition requiring urgent surgery but is often difficult to distinguish from other non-surgical conditions such as urinary infections, pelvic inflammatory disease and non-specific abdominal pain.
- Trial name
- CDAA (NCT03450642)
- Testing
- Observational
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University of Exeter
Hereditary Angioedema (HAE)
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
The purpose of this study is to determine if an investigational treatment is safe and well tolerated when administered by intravenous (IV) infusion in Japanese subjects with HAE.
- Trial name
- NCT02865720
- Testing
- CINRYZE 500 U, CINRYZE 1000 U
- Where
- 10 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Shire
Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy
A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
This is a post-marketing surveillance study conducted as part of the Risk Management Plan (RMP) for South Korea, to evaluate the safety and effectiveness of iptacopan in real-world clinical settings for the treatment of either…
- Trial name
- NCT07416162
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction (MI), Pacemaker Implantation
Augmented Reality as Discharge Information for Hospitalized Cardiology Patients
The goal of this clinical trial is to find out whether a simple augmented reality tool provided at hospital discharge can improve patients' understanding of their care, adherence to treatment, and health outcomes, compared with…
- Conditions
- Myocardial Infarction (MI), Pacemaker Implantation, Heart Failure, Atrial Fibrillation (AF)
- Trial name
- RACAR (NCT07399379)
- Testing
- Augmented reality app
- Where
- Spain
- Volunteers
- 303 people
- Sponsor
- Hospital Universitario Getafe
Hereditary Angioedema
A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161
The purpose of the study is to compare how the body takes up and then eliminates the study drug BCX4161 when it is taken orally as a hard gelatin capsule and as a soft gelatin capsule.
- Trial name
- NCT02125162
- Testing
- BCX4161
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Healthy
Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants
This study is designed to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ALXN2080 in healthy adult participants.
- Trial name
- NCT05428696
- Testing
- ALXN2080
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hereditary Angioedema Types I and II
Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
The objective of this study is to evaluate the safety and tolerability of a single Subcutaneous (SC) dose of Ecallantide in children and adolescents with Hereditary Angioedema (HAE).
- Trial name
- NCT01832896
- Testing
- Ecallantide subcutaneous dosing
- Where
- United States
- Sponsor
- NYU Langone Health
Diabetes, Diabetic Kidney Disease
Immune System in Diabetic Kidney Disease
Diabetes is a chronic condition marked by long-term elevated blood glucose levels. There are more types of diabetes; the majority of patients have type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetic Kidney Disease, Complement System
- Trial name
- KID-CODE (NCT07292493)
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- University Medical Centre Ljubljana